The Classic Myeloproliferative Neoplasms

JAK2 Exon 12 Sequencing: When Not to Use

October 2011

Well, it’s quite clear when we should not do JAK2 exon 12 sequencing. It should not be used as the routine JAK2 screening method in a possible myeloproliferative neoplasm for reasons that I pointed out in the previous slide. Because of the infrequency of exon 12 mutations, sequencing studies should not be done until the much more common JAK2 V617F results are available and, since JAK2 exon 12 mutations occur almost exclusively in PV, these studies should not be done unless the CBC and serum erythropoietin studies raise the possibility of a PV.

< Previous Slide

Exon 12 Sequencing: When Not to Use

Next Slide >

 

Jump to section:

• Introduction
• Optimizing Laboratory Testing for Hematologic Disorders Series
• Goals for Today's Presentation
• Example of a Recent MPN Referral
• Why Do We Have Test Utilization Issues?
• Why Do We Have Test Utilization Issues?
• So What Should We Do?
• WHO Classification
• Important Laboratory Assays in the MPNs
• JAK2 V617F Background
• JAK2 V617F Background
• Question #1 — JAK2 V617F
• JAK2 V617F
• JAK2 V617F at Mayo Clinic
• Conclusion #1 — JAK2 V617F
• JAK2 Exon 12 Sequencing Background
• Question #2 — JAK2 Exon 12 Sequencing
• JAK2 Exon 12 Sequencing: When Not to Use
• JAK2 Exon 12 Sequencing
• Conclusion #2 — JAK2 Exon 12 Sequencing
• MPL Exon 10 Sequencing Studies: Background
• Question #3 — MPL Exon 10 Sequencing
• MPL Exon 10 Sequencing: When to Use
• MPL Exon 10 Sequencing: When Not to Use
• MPL Exon 10 Sequencing
• Conclusion #3 — MPL Exon 10 Sequencing
• Roles of Other Assays in Classic MPN
• Summary
• Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
• Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
• Implementing a Utilization Approach
• Questions